Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Opthalmology

Intra-Arterial Chemotherapy For Retinoblastoma

[1] Vincentius , [1] Antonius

[1] Faculty of Medicine, Sebelas Maret University, Surakarta City, Central Java, Indonesia

Correspondence: dr.vincentius8273628@gmail.com

Article History :

Received date : 2024/10/14
Revised date : 2024/11/29
Accepted date : 2024/12/17
Published date : 2025/01/10

ABSTRACT

Background: The diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration (nAMD) has been a subject of considerable research, revealing both its utility and limitations. **Literature Review**: Subsequent research, including a comprehensive update by Zanaty et al. (Zanaty et al., 2014), underscored the growing adoption of IAC as a first-line treatment for advanced retinoblastoma, particularly in cases where systemic chemotherapy has failed. This shift reflects an increasing recognition of the need for accurate diagnosis and staging, which are essential for effective management (Zanaty et al., 2014). Case studies, such as those by Jiang et al. (Jiang et al., 2021), demonstrated the successful application of IAC in very low birthweight infants, indicating its versatility and potential for broader application in younger populations (Jiang et al., 2021). Liang et al. (Liang et al., 2022) further reinforced the role of IAC as a primary treatment for advanced unilateral retinoblastoma, showcasing its efficacy in increasing drug exposure while minimizing systemic side effects (Liang et al., 2022). Tangella's (Vardhan Tangella, 2023) comprehensive review highlighted the established effectiveness of IAC in high-grade retinoblastoma while cautioning about the persistent risk of micrometastases, emphasizing the necessity for vigilant monitoring and management (Vardhan Tangella, 2023). **Conclusion**: In conclusion, the literature on intra-arterial chemotherapy for retinoblastoma reflects a dynamic landscape marked by promising outcomes and ongoing challenges. The evolution of IAC as a treatment modality highlights its potential to improve patient outcomes, particularly in preserving ocular structures and minimizing systemic toxicity. However, the need for continued research to address the limitations and optimize treatment strategies remains paramount. As the field progresses, the integration of IAC into comprehensive treatment plans that consider individual patient circumstances will be essential for achieving the best possible outcomes in retinoblastoma management.

Keywords: Intra-Arterial Chemotherapy, Retinoblastoma

INTRODUCTION

The literature surrounding intra-arterial chemotherapy (IAC) for retinoblastoma has evolved significantly over the past decade, reflecting advancements in treatment protocols and a deeper understanding of the disease. The foundational work by Kim, Do, and Egbert (Kim et al., 2011) highlighted the potential of IAC as a targeted treatment for advanced intraocular retinoblastoma, noting its advantages over traditional systemic chemotherapy, such as reduced systemic side effects and the ability to treat younger patients without the risks associated with external beam radiation. Their study, however, also illustrated the limitations of IAC, as evidenced by the failure to control vitreous seeding in two patients, which ultimately led to enucleation (Kim et al., 2011).

Building on this, Zanaty et al. (Zanaty et al., 2014) provided a comprehensive update on IAC, emphasizing its increasing adoption as a treatment strategy for advanced retinoblastoma that has failed systemic chemotherapy. They acknowledged the challenges that remain, including the need for accurate diagnosis and staging, which are critical for the effective management of retinoblastoma. Their findings underscored the growing recognition of IAC as a first-line option for certain cases, despite the need to navigate its obstacles (Zanaty et al., 2014).

Recent case studies, such as those by Jiang et al. (Jiang et al., 2021), have illustrated the successful application of IAC in very low birthweight infants, indicating its versatility and potential for broader application. This study adds to the growing body of evidence supporting IAC as a safe and effective treatment modality for younger patients with retinoblastoma (Jiang et al., 2021).

Liang et al. (Liang et al., 2022) further reinforced the role of IAC as a primary treatment for advanced unilateral retinoblastoma in their Chinese cohort, comparing its efficacy to that of intravenous chemotherapy. Their findings indicated that IAC not only increases drug exposure to intraocular tumors but also significantly reduces

systemic side effects, thus enhancing treatment outcomes for advanced cases (Liang et al., 2022).

Finally, Tangella (Vardhan Tangella, 2023) provided a comprehensive review of the evolving role of IAC in both pediatric and adult cancers, reaffirming its established effectiveness in high-grade retinoblastoma. The review noted that while IAC has shown promising results, it does not eliminate the risk of micrometastases, emphasizing the need for continued vigilance in monitoring and managing advanced-stage retinoblastoma (Vardhan Tangella, 2023).

Overall, the literature reflects a dynamic landscape in the application of intra-arterial chemotherapy for retinoblastoma, characterized by promising outcomes, ongoing challenges, and a commitment to optimizing treatment strategies for this complex pediatric malignancy.

LITERATURE REVIEW

The article "Enucleated eyes after failed intra-arterial infusion of chemotherapy for unilateral retinoblastoma: histopathologic evaluation of vitreous seeding" by Kim et al. (Kim et al., 2011) provides a valuable examination of the efficacy and limitations of intra-arterial chemotherapy (IAC) in treating advanced intraocular retinoblastoma, particularly in cases where systemic chemotherapy has failed. The authors highlight the advantages of IAC, including reduced systemic side effects such as myelosuppression and immunosuppression, which are critical considerations when treating pediatric patients, especially those under 12 months of age (Kim et al., 2011).

The study presents two cases of patients with unilateral retinoblastoma who experienced persistent vitreous seeding despite undergoing multiple sessions of IAC. This aspect of the article is particularly significant as it underscores the challenges associated with IAC, specifically the potential for treatment resistance in certain cases. The authors note that despite escalating doses of chemotherapy, the vitreous seeding remained unresponsive, leading to the eventual enucleation of both eyes for tumor control. This outcome raises important questions about the effectiveness of IAC in specific clinical scenarios and suggests that while IAC may

offer a promising alternative to traditional therapies, it is not universally effective for all patients (Kim et al., 2011).

Furthermore, the article contributes to the ongoing discourse regarding the balance between treatment efficacy and the preservation of ocular structures in retinoblastoma management. While IAC has demonstrated high globe salvage rates in some studies, the cases presented here illustrate that treatment outcomes can vary significantly depending on individual patient factors and tumor characteristics. The authors' focus on histopathologic evaluation of the enucleated eyes provides deeper insights into the tumor's behavior and the potential mechanisms underlying treatment failure, which is crucial for developing future therapeutic strategies.

The article "Update on Intra-Arterial Chemotherapy for Retinoblastoma" by Zanaty et al. (Zanaty et al., 2014) provides a comprehensive overview of the evolving landscape of retinoblastoma treatment, particularly emphasizing the role of intra-arterial chemotherapy (IAC) as a viable alternative to enucleation for advanced-stage tumors. The authors highlight the significant progress made in the tools and techniques available for managing retinoblastoma over the past decade, which has led to a paradigm shift in treatment approaches.

One of the key insights from the article is the increasing acceptance of IAC for patients with advanced and refractory retinoblastomas. The authors argue that the primary motivation behind the adoption of IAC is the desire to preserve the eye and avoid enucleation, which can have profound psychological and social implications for patients and their families. The authors present IAC as not only a promising treatment option but also as one that is gaining traction due to its effectiveness and safety profile, thus indicating a shift towards more conservative management strategies in retinoblastoma care.

However, the article does not shy away from addressing the challenges that accompany the implementation of IAC. A critical aspect discussed is the importance of accurate diagnosis and staging of retinoblastoma. The authors emphasize that misdiagnosis can lead to inappropriate treatment, particularly in distinguishing retinoblastoma from pseudoretinoblastomas—conditions that can

mimic retinoblastoma but require different management strategies. The mention of various mimicking lesions, including persistent fetal vasculature and Coats disease, underscores the complexity of diagnosing retinoblastoma and the need for careful evaluation by experienced clinicians.

Moreover, the article suggests that while IAC shows promise, further research is necessary to optimize its application and address the remaining obstacles in the management of retinoblastoma. The authors call for continued advancements in diagnostic techniques and treatment protocols to ensure that patients receive the most effective and appropriate care.

The article titled "망막모세포종 환자를 대상으로 한 동맥 항암 및 전신 항암 병용 요법의 효과" by 한승민 (, 2016) presents a comprehensive evaluation of the efficacy of intra-arterial chemotherapy (IAC) combined with intravenous chemotherapy (IVC) in treating retinoblastoma, a malignant tumor of the retina predominantly affecting children. The study encompasses data collected between January 2012 and December 2014, involving 13 eyes from 12 patients diagnosed with retinoblastoma at the Yonsei Cancer Center.

A critical aspect of the study is its focus on eye salvage rates, which are measured by the eye preservation time—the interval from diagnosis to the point of enucleation. This metric is crucial, as it reflects not only the effectiveness of the treatment in preventing the loss of the eye but also the overall management of retinoblastoma in terms of maintaining quality of life for pediatric patients. The classification of the eyes according to the International Classification of Retinoblastoma (ICRB) into groups B, C, D, and E provides a structured framework for understanding the severity of the cases treated, with a notable concentration in the more advanced groups (D and E).

The results indicate that IAC, administered three to five times per eye and totaling 54 procedures, alongside five to fifteen courses of IVC, yielded a high survival rate among the patients, with no significant complications reported. This finding underscores the treatment’s tolerability, which is particularly relevant given the

delicate nature of pediatric oncology and the potential for adverse effects in young patients. Furthermore, the article emphasizes the evolution of treatment goals in developed countries, shifting from mere survival to also prioritizing eye preservation, vision maintenance, and complication minimization.

The introduction of IAC in the early 2000s marks a significant advancement in the therapeutic landscape for retinoblastoma, particularly for advanced stages of the disease. The study effectively highlights the potential of IAC as a viable option for eye salvage, reinforcing its role in contemporary treatment paradigms. However, while the findings are promising, the relatively small sample size and the retrospective nature of the study warrant caution in generalizing the results. Future research with larger cohorts and prospective designs would be beneficial to further validate the efficacy and safety of IAC in diverse patient populations.

The article "The Role of Intraarterial Chemotherapy in the Management of Retinoblastoma" by Pekacka (Pekacka, 2020) provides a comprehensive overview of the application of intra-arterial chemotherapy (IAC) in treating retinoblastoma, particularly emphasizing its role as a first-line treatment for specific groups of the disease. The author delineates the indications for IAC, highlighting its effectiveness in unilateral retinoblastoma (groups B, C, and D) and bilateral retinoblastoma (groups D and E). This classification is crucial as it guides clinicians in determining the most appropriate therapeutic approach based on the disease's progression and staging.

Pekacka notes a significant divergence in clinical practice, where some healthcare providers opt for systemic chemotherapy, especially in cases of bilateral retinoblastoma. This preference is largely attributed to concerns regarding the unpredictable vascular toxicity associated with IAC and the need for chemoprotection against potential metastasis and the risk of developing trilateral retinoblastoma. This critical evaluation of treatment modalities underscores the complexity of managing retinoblastoma and the necessity for individualized patient care strategies.

The article also addresses the role of IAC as a secondary treatment option for recurrent or persistent tumors and subretinal seeds, which is an important consideration in the management of retinoblastoma. This indicates that while IAC is beneficial, it is not a one-size-fits-all solution and must be contextualized within the patient's overall treatment plan.

Furthermore, Pekacka highlights the limitations of IAC, specifically the contraindications that may prevent its implementation. This aspect is particularly noteworthy as it emphasizes the need for thorough patient assessment before proceeding with IAC. Additionally, the discussion on the dosimetric impact of fluoroscopy radiation exposure on internal organs is a critical consideration that must be weighed against the potential benefits of the treatment. The author effectively raises awareness about the safety concerns associated with IAC, which is essential for informed decision-making in clinical practice.

The article by Jiang et al. (Jiang et al., 2021) presents a compelling exploration of intra-arterial chemotherapy (IAC) as a treatment modality for retinoblastoma in very low birthweight infants. The authors provide two case reports that illustrate the application of IAC in a population that is often overlooked in the literature due to the inherent risks associated with low birthweight and the complexities of managing retinoblastoma in such vulnerable patients.

The authors begin by contextualizing the significance of IAC in the treatment of retinoblastoma, highlighting its efficacy in both unilateral and bilateral cases, as well as in patients with varied stages of intraocular disease. This is particularly relevant given the challenges that arise in treating retinoblastoma in infants, who may be at increased risk for complications and adverse effects from conventional systemic chemotherapy. Jiang et al. (Jiang et al., 2021) effectively argue that IAC offers a targeted approach, minimizing systemic exposure while delivering high local drug concentrations directly to the tumor site.

The case reports presented are noteworthy for their detailed documentation of the clinical processes, outcomes, and follow-up care of the two infants. The authors meticulously outline the methodology of the IAC procedure, which includes

catheter placement and drug administration, providing a clear framework for replication in future cases. This methodological rigor is crucial for advancing the understanding of IAC in this specific patient demographic.

In terms of outcomes, the authors report positive results, including tumor regression and preservation of visual function, which underscores the potential of IAC as a viable treatment option for very low birthweight infants with retinoblastoma. However, the article would benefit from a more extensive discussion on the long-term implications of IAC in this population, particularly concerning potential side effects and the need for ongoing monitoring.

Moreover, while the authors make a strong case for the safety and efficacy of IAC in these cases, it is important to consider the limitations inherent in case report studies. The sample size is small, and the findings may not be generalizable to a broader population. Future research should aim to include larger cohorts and comparative studies to validate these findings and establish more definitive conclusions regarding the role of IAC in treating retinoblastoma in very low birthweight infants.

The article "Intra-Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China" by Liang et al. (Liang et al., 2022) presents a significant contribution to the understanding and management of advanced unilateral retinoblastoma, a condition that poses considerable challenges in pediatric oncology. The authors articulate the limitations of traditional intravenous chemotherapy (IVC), which has been the standard treatment for retinoblastoma since the mid-1990s. They emphasize that while IVC has been widely utilized, its efficacy in cases of advanced retinoblastoma is limited, with treatment success rates falling below 50%. This statistic underscores the necessity for alternative therapeutic strategies that can enhance treatment outcomes while minimizing adverse effects.

The introduction of intra-arterial chemotherapy (IAC) marks a pivotal shift in the management paradigm for retinoblastoma. The authors argue convincingly that IAC offers substantial advantages over IVC, primarily through the direct delivery

of chemotherapeutic agents into the ocular region. This targeted approach not only increases the concentration of the drugs at the tumor site, thereby improving intraocular exposure, but also significantly reduces systemic toxicity, which is a critical concern in pediatric patients undergoing cancer treatment.

Liang et al. (Liang et al., 2022) provide a thorough evaluation of the efficacy and complications associated with IAC in their study population. The findings indicate that IAC has the potential to salvage many eyes that would otherwise necessitate enucleation, thus preserving vision and improving the quality of life for affected children. The authors present data that supports the notion that IAC can be a primary treatment modality for advanced unilateral retinoblastoma, which is a substantial advancement in the field.

Moreover, the article delves into the complications associated with IAC, which, while generally lower than those linked to IVC, still warrant careful consideration. The authors advocate for a balanced approach to treatment, emphasizing the importance of monitoring and managing potential adverse effects to optimize patient outcomes.

The article "The Evolving Role of Intra-arterial Chemotherapy in Adult and Pediatric Cancers: A Comprehensive Review" by Tangella (Vardhan Tangella, 2023) provides an insightful examination of intra-arterial chemotherapy (IAC) and its applications, particularly focusing on pediatric cancers such as retinoblastoma. The author articulates the growing significance of IAC, emphasizing its integration with various therapeutic modalities to enhance treatment outcomes.

Tangella highlights that the primary application of IAC in the pediatric population is in managing retinoblastoma, a critical insight given the disease's unique challenges and treatment necessities. The article references early studies that established IAC's definitive role in treating high-grade retinoblastoma. This is particularly relevant, as high-grade cases often pose significant risks for ocular and systemic complications. The author notes a specific study where melphalan IAC was administered every 21 days, resulting in ocular salvage in seven out of twelve

eyes. This statistic underscores the efficacy of IAC in preserving vision in affected patients, which is a paramount consideration in pediatric oncology.

However, the article also raises an important caveat regarding the limitations of IAC, particularly in the context of advanced-stage retinoblastoma. The potential for occult micrometastases remains a significant concern, indicating that while IAC can be effective, it should not be viewed as a standalone treatment. This critical evaluation suggests that clinicians must remain vigilant and consider comprehensive treatment strategies that may include adjunctive therapies to mitigate the risk of metastasis.

CONCLUSION

The literature surrounding intra-arterial chemotherapy (IAC) for retinoblastoma reveals a significant evolution in treatment approaches, highlighting both the promising potential and the ongoing challenges associated with this modality. Early foundational studies, such as that by Kim et al. (Kim et al., 2011), established IAC as a targeted treatment for advanced intraocular retinoblastoma, emphasizing its advantages over systemic chemotherapy, including reduced systemic side effects and the ability to treat younger patients (Kim et al., 2011). However, the study also pointed out critical limitations, particularly concerning uncontrolled vitreous seeding, which can lead to enucleation.

Subsequent research, including a comprehensive update by Zanaty et al. (Zanaty et al., 2014), underscored the growing adoption of IAC as a first-line treatment for advanced retinoblastoma, particularly in cases where systemic chemotherapy has failed. This shift reflects an increasing recognition of the need for accurate diagnosis and staging, which are essential for effective management (Zanaty et al., 2014). Case studies, such as those by Jiang et al. (Jiang et al., 2021), demonstrated the successful application of IAC in very low birthweight infants, indicating its versatility and potential for broader application in younger populations (Jiang et al., 2021). Liang et al. (Liang et al., 2022) further reinforced the role of IAC as a primary treatment for advanced unilateral retinoblastoma, showcasing its efficacy

in increasing drug exposure while minimizing systemic side effects (Liang et al., 2022).

Tangella's (Vardhan Tangella, 2023) comprehensive review highlighted the established effectiveness of IAC in high-grade retinoblastoma while cautioning about the persistent risk of micrometastases, emphasizing the necessity for vigilant monitoring and management (Vardhan Tangella, 2023). The literature collectively indicates that while IAC presents a promising alternative to traditional therapies, it is not without limitations. The effectiveness of IAC can vary significantly based on individual patient factors and tumor characteristics, necessitating a tailored approach to treatment.

In conclusion, the literature on intra-arterial chemotherapy for retinoblastoma reflects a dynamic landscape marked by promising outcomes and ongoing challenges. The evolution of IAC as a treatment modality highlights its potential to improve patient outcomes, particularly in preserving ocular structures and minimizing systemic toxicity. However, the need for continued research to address the limitations and optimize treatment strategies remains paramount. As the field progresses, the integration of IAC into comprehensive treatment plans that consider individual patient circumstances will be essential for achieving the best possible outcomes in retinoblastoma management.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Kim, J., Do, H., & Egbert, P., 2011. Enucleated eyes after failed intra-arterial infusion of chemotherapy for unilateral retinoblastoma: histopathologic evaluation of vitreous seeding. ncbi.nlm.nih.gov
2. Zanaty, M., Barros, G., Chalouhi, N., M. Starke, R., Manasseh, P., I. Tjoumakaris, S., L. Shields, C., Hasan, D., Bulsara, K., H. Rosenwasser, R., & Jabbour, P., 2014. Update on Intra-Arterial Chemotherapy for Retinoblastoma. ncbi.nlm.nih.gov
3. Jiang, H., Jiang, Y., Liu, Z., Guo, Y., & Zhang, J., 2021. Intra-arterial chemotherapy for treatment of very low birthweight infants with retinoblastoma: Two case reports. ncbi.nlm.nih.gov
4. Liang, T., Zhang, X., Li, J., Hua, X., Zhao, P., & Ji, X., 2022. Intra-Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China. ncbi.nlm.nih.gov
5. Vardhan Tangella, A., 2023. The Evolving Role of Intra-arterial Chemotherapy in Adult and Pediatric Cancers: A Comprehensive Review. ncbi.nlm.nih.gov
6. , 한승민, 2016. 망막모세포종 환자를 대상으로 한 동맥 항암 및 전신 항암 병용 요법의 효과. [PDF]
7. Pekacka, A., 2020. The Role of Intraarterial Chemotherapy in the Management of Retinoblastoma. ncbi.nlm.nih.gov